Education
About Us
Working with TipRanks
Follow Us
GRI Bio (GRI)
NASDAQ:GRI
GRI Stock Chart & Stats
$2.05
-$0.06(-7.48%)
At close: 4:00 PM EST
$2.05
-$0.06(-7.48%)
Day’s Range― - ―
52-Week Range$1.10 - $30.43
Previous CloseN/A
Volume96.89K
Average Volume (3M)2.35M
Market Cap
$4.88M
Enterprise Value-$2.18M
Total Cash (Recent Filing)$5.12M
Total Debt (Recent Filing)$96.00K
Price to Earnings (P/E)―
Beta2.36
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding2,515,305
10 Day Avg. Volume215,272
30 Day Avg. Volume2,352,435
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.11
P/FCF Ratio-0.30
Enterprise Value/Market Cap-0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit727.12
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$22.50Price Target Upside997.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe Independent Data Monitoring Committee recommended the Phase 2 can continue as planned as no safety concerns were reported.
Safety ProfileTwo and six-week interim safety data from the Phase 2a study demonstrate that GRI-0621 is well-tolerated in the first 24 patients.
Bears Say
Data RequirementsMore patient data is required to appropriately evaluate GRI-0621's full anti-fibrotic effect and capacity to improve pulmonary function.
GRI Bio News
GRI FAQ
What was GRI Bio’s price range in the past 12 months?
GRI Bio lowest stock price was $1.10 and its highest was $30.43 in the past 12 months.
What is GRI Bio’s market cap?
GRI Bio’s market cap is $4.88M.
When is GRI Bio’s upcoming earnings report date?
GRI Bio’s upcoming earnings report date is May 20, 2026 which is in 209 days.
How were GRI Bio’s earnings last quarter?
GRI Bio released its earnings results on Aug 13, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.31 by -$0.08.
Is GRI Bio overvalued?
According to Wall Street analysts GRI Bio’s price is currently Undervalued.
Does GRI Bio pay dividends?
GRI Bio does not currently pay dividends.
What is GRI Bio’s EPS estimate?
GRI Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GRI Bio have?
GRI Bio has 2,515,305 shares outstanding.
What happened to GRI Bio’s price movement after its last earnings report?
GRI Bio reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.31. Following the earnings report the stock price went up 3.175%.
Which hedge fund is a major shareholder of GRI Bio?
Currently, no hedge funds are holding shares in GRI
Company Description
GRI Bio
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Stock 12 Month Forecast
Average Price Target
$22.50
▲(997.56% Upside)
Technical Analysis
Ownership Overview
22.77%
Insiders
0.16% Mutual Funds
0.34% Other Institutional Investors
76.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---